Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma

medRxiv 2026 Preprint Open access

Read full text
Authors: Eudora Lee, Ralina Karagenova, Charles Lu, Parisa Farokh, Marjan Azin, Federico Repetto, Soma Jobbagy, Rosalynn M. Nazarian, Kerry Reynolds, Shadmehr Demehri, Philip J. Saylor, Lirit Fuksman
+1 more Yevgeniy Semenov
DOI: 10.64898/2026.05.19.26353579
Cited by: 1
References: 24

Abstract

Abstract Key Points Question Among patients with advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV), is development of EV-induced cutaneous adverse events (cAEs) associated with improved survival, and how does this association compare with cutaneous immune-related adverse events (cirAEs)? Findings In a multi-institutional retrospective cohort study, EV-induced cAEs were associated with significantly progression-free survival (hazard ratio, 0.60; 95% CI 0.31-0.67, p

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Nonmelanoma Skin Cancer Studies Dermatology and Skin Diseases

Publication details

Journal / source
medRxiv
Publisher
openRxiv
Publication date
21 May 2026
Language
EN
Document type
Preprint